Investigators evaluate compliance with CCH treatment for Peyronie disease

In this video, Muhammed A. Moukhtar Hammad, MBBCh, discusses the study “Are Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease Compliant? A Seven Years Analysis From a Tertiary Care Men's Health Center,” which he presented at the 2024 Sexual Medicine Society of North America Fall Scientific Meeting in Scottsdale, Arizona. Hammad is a Masters of Biomedical and Translational Science Candidate at the University of California, Irvine (UCI) School of Medicine and a clinical research fellow at UCI Health – Department of Urology.

Transcription:

Please discuss your SMSNA 2024 study "Are Patients Undergoing Intralesional Injection Therapy for Peyronie's Disease Compliant? A Seven Years Analysis From a Tertiary Care Men's Health Center."

Xiaflex, as you know, has become a preferred modality for the treatment of Peyronie disease, and therefore we wanted to explore the outcomes, the compliance rates, the complications with regards to Xiaflex. We defined compliance as having at least 4 cycles of Xiaflex, or they terminated the treatment, per the actual satisfactionrates that they have. So if the patient was satisfied with the treatment, they can stop midway. We actually defined that based on those 2 rules. And then we looked at patients who underwent Xiaflex treatment in a single academic institution, which was theUniversity of California, Irvine, with Dr [Faysal] Yafi. We looked at patients from 2017 till 2023 and when we did that, we tried to look at their demographics and how they are actually compliant. We had a high compliance rate of approximately 70%, but we strive for perfection. Why were the rest not compliant? That was a big question. So we tried to break down the non compliance into a nice pie chart, if you have a look at the poster, and then the majority had unidentifiable causes. But the other reasons that were a little bit interesting was, for example, 6% had a change of insurance plans, and that's why they stopped taking Xiaflex. Others, midway, wanted to opt for surgical options, which was another thing. Then we looked at other reasons for noncompliance. One of the things that they stopped the treatment for is that midway, they just had satisfactory results, which is interesting, because we normally have patients go at least 4 cycles. So looking at these results, we tried to see the reasons for noncompliance. I think this helps the scientific community to know the reasons for these noncompliance. And with these findings, we can actually see the reasons, and we try to solve the reasons for this, and with this, we try to improve their compliance rates, and we try to improve the overall outcomes that we have for Xiaflex treatment in patients with Peyronie disease. This transcript was AI generated and edited by human editors for clarity.